{"id":746791,"date":"2023-04-11T16:30:30","date_gmt":"2023-04-11T20:30:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/voting-rights-and-shares-capital-of-the-company-4\/"},"modified":"2023-04-11T16:30:30","modified_gmt":"2023-04-11T20:30:30","slug":"voting-rights-and-shares-capital-of-the-company-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/voting-rights-and-shares-capital-of-the-company-4\/","title":{"rendered":"Voting Rights and Shares Capital of the Company"},"content":{"rendered":"
\n

PARIS, April 11, 2023 (GLOBE NEWSWIRE) —
<\/em><\/strong><\/p>\n

\n
\n In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorit\u00e9 des March\u00e9s Financiers)<\/em>
\n <\/strong>
\n \n <\/p>\n

\n Paris, France, April 11, 2023<\/strong>
\n
Market: Euronext Paris\u00a0\/ Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com<\/a><\/p>\n\n\n\n\n
\n Date<\/strong><\/p>\n<\/td>\n\n Number of Shares Outstanding<\/strong><\/p>\n<\/td>\n\n Total number of voting rights<\/strong>\n <\/td>\n<\/tr>\n
\n Total voting rights, theoretical<\/strong>
\n
\n 1<\/strong>
\n <\/sup><\/p>\n<\/td>\n		\n Total voting rights, <\/strong>
\n
\n exercisable<\/strong>
\n
\n 2<\/strong>
\n <\/sup>\n <\/td>\n<\/tr>\n
March 31, 2023<\/p>\n<\/td>\n34,875,872<\/td>\n36,634,849<\/td>\n36,612,731<\/td>\n<\/tr>\n<\/table>\n

According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix\u2019s capital if those figures differ from the information previously disclosed.<\/p>\n

\n About NANOBIOTIX<\/strong>\n <\/p>\n

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.\u00a0<\/p>\n

For more information about Nanobiotix, visit us at www.nanobiotix.com<\/u><\/a> or follow us on LinkedIn<\/u><\/a> and Twitter<\/u><\/a>.<\/u>\u00a0<\/p>\n

\n Contacts<\/strong>\n <\/p>\n\n\n\n\n\n
\n Nanobiotix <\/em>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

Nanobiotix Communications<\/strong>
\n
\n Brandon Owens<\/em>
\n
\n VP, Communications<\/em>
\n
+1 (617) 852-4835
contact@nanobiotix.com<\/u><\/p>\n<\/td>\n

\n

Nanobiotix Investor Relations <\/strong>
\n
\n Craig West<\/em>
\n
\n SVP, Investor Relations<\/em>
\n
+1 (617) 583-0211\u00a0
investors@nanobiotix.com<\/u><\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Media Relations<\/em>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
France \u2013 Ulysse Communication <\/strong>
Pierre-Louis Germain
+ 33 (0) 6 64 79 97 51
plgermain@ulysse-communication.com<\/a><\/p>\n<\/td>\n		\n LifeSci Advisors<\/strong>\u00a0
Ligia Vela-Reid<\/em>\u00a0
+44 (0) 7413825310\u00a0
lvela-reid@lifesciadvisors.com<\/u>\u00a0<\/p>\n<\/td>\n		\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\u00a0<\/p>\n

\n 1<\/sup>
\n The total number of theoretical (or \u201cgross\u201d) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.<\/em>\n <\/p>\n

\n 2<\/sup>
\n The total number of exercisable at a Shareholders\u2019 Meeting (or \u201cnet\u201d) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.<\/em>\n <\/p>\n

\u00a0<\/p>\n

\n Attachment<\/strong>\n <\/p>\n